Denali Therapeutics agrees to sell rare pediatric disease priority review voucher for USD 195 million

Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLI

0.00
  • Denali entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 195 million.
  • The voucher was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
  • Proceeds are expected to support development of its TransportVehicle-enabled pipeline in lysosomal storage disorders, Alzheimer’s disease, Parkinson’s disease.
  • Closing is subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.